Autor: |
P, Beuzeboc, S, Scholl, X S, Garau, A, Vincent-Salomon, P D, Cremoux, J, Couturier, T, Palangié, P, Pouillart |
Jazyk: |
francouzština |
Rok vydání: |
1999 |
Předmět: |
|
Zdroj: |
Bulletin du cancer. 86(6) |
ISSN: |
0007-4551 |
Popis: |
HER2 is overexpressed in about 25% to 30% of breast cancers and associated with poor prognosis, resistance to hormonotherapy and lack of sensitivity to CMF-based adjuvant chemotherapy. Herceptin (trastuzumab), a humanized monoclonal antibody, administered as a single agent, produces objective responses in phase II trials in patients with metastatic breast cancers overexpressing HER2. It has shown a substantial benefit in a phase III trial which compares a standard first line chemotherapy (doxorubicin and cyclophosphamide or taxol alone) to the same chemotherapy with Herceptin in metastatic breast cancer. The Herceptin arm had significantly higher response rate (+ 53%), an improvement in the median duration of response (+ 57%) as well as in time to progression (+ 65%) compared to chemotherapy alone. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|